Benzinga | Jan 24, 2022 07:07AM EST

Connect Biopharma Presents Data And Analyses From The Global Phase 2b Trial Of CBP-201 At The Maui Derm Conference

--Data provides detailed results, with achievement of both primary and key secondary end points and demonstrating significant improvements in skin clearance, disease severity, and itch compared to placebo

--Analyses demonstrate that the benefits of CBP-201 to patients continue to increase as baseline disease severity increases --

--Data and analyses support the potential for a highly competitive efficacy and safety profile for CBP-201 that includes a differentiated Q4W dosing schedule --